224 related articles for article (PubMed ID: 24269835)
1. Reducing attrition in drug development: smart loading preclinical safety assessment.
Roberts RA; Kavanagh SL; Mellor HR; Pollard CE; Robinson S; Platz SJ
Drug Discov Today; 2014 Mar; 19(3):341-7. PubMed ID: 24269835
[TBL] [Abstract][Full Text] [Related]
2. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
[TBL] [Abstract][Full Text] [Related]
3. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
Kramer JA; Sagartz JE; Morris DL
Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
[TBL] [Abstract][Full Text] [Related]
4. Good Laboratory Practice (GLP) status of Asian countries and its implementation in non-clinical safety studies in pharmaceutical drug development.
Sasaki M; Hinotsu S; Kawakami K
J Toxicol Sci; 2009 Oct; 34(5):493-500. PubMed ID: 19797857
[TBL] [Abstract][Full Text] [Related]
5. Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules.
Luker T; Alcaraz L; Chohan KK; Blomberg N; Brown DS; Butlin RJ; Elebring T; Griffin AM; Guile S; St-Gallay S; Swahn BM; Swallow S; Waring MJ; Wenlock MC; Leeson PD
Bioorg Med Chem Lett; 2011 Oct; 21(19):5673-9. PubMed ID: 21852131
[TBL] [Abstract][Full Text] [Related]
6. Methodological innovations expand the safety pharmacology horizon.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
[TBL] [Abstract][Full Text] [Related]
7. Computational toxicology--a tool for early safety evaluation.
Merlot C
Drug Discov Today; 2010 Jan; 15(1-2):16-22. PubMed ID: 19835978
[TBL] [Abstract][Full Text] [Related]
8. Stem cell models for drug discovery and toxicology studies.
Liu W; Deng Y; Liu Y; Gong W; Deng W
J Biochem Mol Toxicol; 2013 Jan; 27(1):17-27. PubMed ID: 23293059
[TBL] [Abstract][Full Text] [Related]
9. Lessons learned from candidate drug attrition.
Empfield JR; Leeson PD
IDrugs; 2010 Dec; 13(12):869-73. PubMed ID: 21154145
[TBL] [Abstract][Full Text] [Related]
10. The non-GLP toleration/dose range finding study: design and methodology used in an early toxicology screening program.
Herlich JA; Taggart P; Proctor J; Stahle P; Colis R; Hall L; Pugsley MK
Proc West Pharmacol Soc; 2009; 52():94-8. PubMed ID: 22128433
[TBL] [Abstract][Full Text] [Related]
11. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
[TBL] [Abstract][Full Text] [Related]
12. Race is on to find alternative to animal tests.
Goodman S
Nature; 2002 Jul; 418(6894):116. PubMed ID: 12110854
[No Abstract] [Full Text] [Related]
13. Investigative safety science as a competitive advantage for Pharma.
Moggs J; Moulin P; Pognan F; Brees D; Leonard M; Busch S; Cordier A; Heard DJ; Kammüller M; Merz M; Bouchard P; Chibout SD
Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1071-82. PubMed ID: 22769724
[TBL] [Abstract][Full Text] [Related]
14. Safety pharmacology investigations in toxicology studies: an industry survey.
Authier S; Vargas HM; Curtis MJ; Holbrook M; Pugsley MK
J Pharmacol Toxicol Methods; 2013; 68(1):44-51. PubMed ID: 23685201
[TBL] [Abstract][Full Text] [Related]
15. Dogs and monkeys in preclinical drug development: the challenge of reducing and replacing.
Pellegatti M
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1171-80. PubMed ID: 23705836
[TBL] [Abstract][Full Text] [Related]
16. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition.
Giri S; Bader A
Drug Discov Today; 2011 May; 16(9-10):382-97. PubMed ID: 21354326
[TBL] [Abstract][Full Text] [Related]
17. Advances in the development and use of human tissue-based techniques for drug toxicity testing.
Clotworthy M; Archibald K
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1155-69. PubMed ID: 23687950
[TBL] [Abstract][Full Text] [Related]
18. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
Buckley LA; Dorato MA
Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
[TBL] [Abstract][Full Text] [Related]
19. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
[TBL] [Abstract][Full Text] [Related]
20. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
